Divi's Laboratories reported a strong fiscal year 2026 with profit after tax at ₹2,607 crore, a 18% jump. Revenue grew 13% to ₹10,388 crore. The company invested over ₹1,500 crore in expansion.
Divi's Laboratories FY26: Profit Jumps 18% to ₹2,607 Crore on 13% Revenue Growth
Profit After Tax: ₹2,607 crore
Revenue from operations: ₹10,388 crore
Reader Takeaway: Strong profit and revenue growth driven by custom synthesis, with significant capex for future expansion.
What just happened
Divi's Laboratories announced its financial results for the fiscal year 2025-26. The company reported a Profit After Tax (PAT) of ₹2,607 crore, an increase of 18.02% compared to the previous year. Revenue from operations saw a 12.94% rise, reaching ₹10,388 crore. Earnings Per Share (EPS) stood at ₹98.19. The company also recommended a dividend of ₹30 per share.
Why this matters
This performance indicates robust operational growth and improved profitability for Divi's Labs. The significant investment in capacity expansion and the inauguration of a Peptide Centre of Excellence suggest a strategic focus on high-value products and future growth drivers. The successful US FDA inspection also reinforces the company's commitment to quality and regulatory compliance, crucial for its international business.
The backstory
Divi's Laboratories has consistently focused on its core portfolios: Generic APIs, Custom Synthesis, and Nutraceuticals. Custom Synthesis has been identified as a key growth driver, supported by a strong project pipeline. The company has also been investing in backward integration to improve cost competitiveness and operational efficiency.
What changes now
The substantial capital expenditure of over ₹1,500 crore in FY 2025-26 is aimed at expanding its manufacturing network, creating capacity, and upgrading technology. The new Peptide Centre of Excellence is expected to boost capabilities in complex peptide synthesis. Unit 3 at Kakinada will continue to support backward integration efforts.
Risks to watch
Investors should monitor input cost risks arising from geopolitical uncertainties and trade policy changes, which could impact sourcing costs and lead times. Additionally, persistent pricing pressure in the generic API segment could moderate value growth for this core portfolio.
Peer comparison
Divi's Laboratories operates in the pharmaceutical sector, specifically focusing on Active Pharmaceutical Ingredients (APIs) and Custom Synthesis. Key competitors include companies like Aarti Drugs, Laurus Labs, and Solara Active Pharma Sciences, though Divi's unique scale and integrated model offer distinct advantages.
Context metrics (time-bound)
- Total Income: ₹10,894 crore (FY 2025-26)
- Revenue from operations: ₹10,388 crore (FY 2025-26), a 12.94% increase year-on-year.
- EBITDA: ₹3,920 crore (FY 2025-26), a 17.68% increase.
- Profit Before Tax (PBT): ₹3,436 crore (FY 2025-26), a 17.31% increase.
- Profit After Tax (PAT): ₹2,607 crore (FY 2025-26), an 18.02% increase.
- Capex: Over ₹1,500 crore invested in FY 2025-26.
- Dividend: ₹30 per share recommended.
What to track next
Investors will be keen to observe the contribution of new capacity investments to future growth over the next 12-24 months. Monitoring the impact of global supply chain risks and competitive pricing on margins will also be crucial.